|
By Simran Silva Š2006 Bollyvista.com |
|
|
Shah Rukh Khan |
It is estimated that about nine million new cancer cases are diagnosed globally every year of which over half are fatal. In India, there are an estimated 7,00,000 new cancer patients every year and half of them do not survive. The South East Asian region accounts for the highest incidence of head and neck cancers and one-third of the world burden of head and neck cancers are reported in the Indian subcontinent.
On Sunday, September 17th, Shah Rukh Khan, whose father succumbed to the disease back in 1981 and Bangalore-based Biocon Ltd. will launch the much-awaited new drug BIOMAb EGFR to treat head and neck cancers. The drug had shown consistent results when clinical trials were conducted on patients suffering from head and neck cancers, both in India and abroad.
This is Biocon's first proprietary product. It has received the requisite regulatory approvals for commercial marketing in India and overseas. While the first batch of the new drug will be imported from Cuba, Biocon will subsequently manufacture the cancer-fighting drug at its facility Biocon Park in Bangalore. |
SEARCH
